Compare Amylx Pharmaceuticals Inc (AMLX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs TotalEnergies SE — how do they compare? Amylx Pharmaceuticals Inc trades at $17.31 (market cap $1.98B), while TotalEnergies SE trades at $80.22 (market cap $173.13B). The key difference: TotalEnergies SE is far larger — about 87.4× Amylx Pharmaceuticals Inc's market cap, and TotalEnergies SE pays a 5.37% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | TTE | |
|---|---|---|
Market Cap | $1.98B | $173.13B |
Sector | Health | Energy |
52-Week High | $18.70 | $93.60 |
52-Week Low | $7.64 | $57.39 |
Enterprise Value | $1.70B | $207.27B |
Dividend Yield | — | 5.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
TTE trades at $78.5, up 0.35% today, with a neutral technical signal and mixed earnings history including a Q1 2026 beat. Valuation ratios appear attractive with a P/E of 11.65 and EV/EBITDA of 4.81. Recent news highlights strategic divestments and new LNG shipments, while cash flow trends show stabilization after recent declines.
Outlook is cautiously positive given strong analyst buy ratings (57.58%) and shareholder returns via dividends, but risks include revenue declines, geopolitical exposure, and regulatory pressures. The stock offers value characteristics with moderate growth prospects amid energy sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
